Hippocratic AI has raised $126 million in a Series C round at a $3.5 billion valuation, bringing its total funding to $404 million just ten months after its previous raise. Led by Avenir Growth with participation from CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, and others, the funding reflects growing investor confidence in the company’s mission to deploy safe, responsible generative AI in healthcare. Founded by CEO Munjal Shah alongside physicians, researchers, and technologists from leading institutions like Stanford, Johns Hopkins, Microsoft, and Google, Hippocratic AI develops generative AI agents that assist both clinicians and patients with tasks such as chronic care management, medication checks, and post-discharge follow-ups—all accessible via its Healthcare AI Agent App Store.
Clinician collaboration is central to Hippocratic AI’s approach: healthcare professionals can design, test, and deploy AI agent prototypes within hours and share in the revenue generated when other organizations use their creations. Each agent undergoes extensive safety testing before release, reflecting the company’s commitment to its namesake “do no harm” principle. In just 15 months, Hippocratic AI has partnered with over 50 major health systems and completed more than 115 million patient interactions without safety incidents. Investors such as Andreessen Horowitz’s Julie Yoo praised its rapid growth as evidence of AI’s ability to address workforce shortages and patient access challenges, while Shah noted the new funding will fuel global expansion, partnerships, and continued innovation.